Bioxytran Launches Joint Venture with the Heme Foundation for Development of Universal Oxygen Carrier
The Heme Foundation and Bioxytran join forces to address the global blood supply shortage
BOSTON, MASSACHUSETTS, July 18, 2024 (GLOBE NEWSWIRE) — BIOXYTRAN, INC. (OTCQB:BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral diseases, and stroke, is pleased to announce a Joint Venture (the “JV”) with the Heme Foundation (“Heme” or the “Foundation”) to develop a Universal Oxygen Carrier (“UOC”) as an alternative to blood transfusions. Bioxytran will retain all intellectual property regarding this agreement and the Foundation will be granted a right of use for blood transfusion in exchange for their pledge of up to $10 million over the course of the project’s development. To date, the JV has invested over $2 million in prototypes and in the development of compounds.
Related news for (BIXT)
- Bioxytran’s Groundbreaking Stroke & Alzheimer’s Tech Gains Validation That Measures Oxygenation Uptake During Strokes
- Bioxytran’s Antiviral Breakthrough Featured in University of Georgia’s $100M HPAI Poultry Innovation Grand Challenge Submission
- Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
- Bioxytran Marks 50 years of Mitochondrial Research with BXT-25 Advancements
- Bioxytran Signs NDA with the University of Georgia to Evaluate Galectin Antagonists for Bird Flu Treatment in Chickens